Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone therapeutic drug monitoring versus standard dosing in metastatic castration-resistant prostate cancer
NL-OMON61036Phase 4Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of abiraterone in prostate cancer (PCa) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Radiographic progression-free survival. Planned start May 2026; status: not yet recruiting.
02
Drugs
abiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON61036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61036.